These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 20932066)

  • 1. Dopamine receptor agonists for the treatment of early or advanced Parkinson's disease.
    Perez-Lloret S; Rascol O
    CNS Drugs; 2010 Nov; 24(11):941-68. PubMed ID: 20932066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials.
    Kulisevsky J; Pagonabarraga J
    Drug Saf; 2010 Feb; 33(2):147-61. PubMed ID: 20082541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease.
    Antonini A; Poewe W
    Lancet Neurol; 2007 Sep; 6(9):826-9. PubMed ID: 17706566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of dopamine receptor agonists in the treatment of early Parkinson's disease.
    Bonuccelli U; Del Dotto P; Rascol O
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S44-53. PubMed ID: 20123557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spotlight on rotigotine in Parkinson's disease.
    Baldwin CM; Keating GM
    Drugs Aging; 2008; 25(2):175-7. PubMed ID: 18257604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pramipexole. A review of its use in the management of early and advanced Parkinson's disease.
    Dooley M; Markham A
    Drugs Aging; 1998 Jun; 12(6):495-514. PubMed ID: 9638397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pergolide in the treatment of patients with early and advanced Parkinson's disease.
    Bonuccelli U; Colzi A; Del Dotto P
    Clin Neuropharmacol; 2002; 25(1):1-10. PubMed ID: 11852289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Dopaminergic agonists in the treatment of Parkinson's disease].
    Supiot F; Sternon J; Zegers de Beyl D
    Rev Med Brux; 2000 Dec; 21(6):493-9. PubMed ID: 11194495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K; Lyons KE
    Pharmacotherapy; 2009 Dec; 29(12):1452-67. PubMed ID: 19947805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson's disease.
    Linazasoro G;
    J Neurol; 2004 Mar; 251(3):335-9. PubMed ID: 15015015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis.
    Etminan M; Gill S; Samii A
    Drug Saf; 2003; 26(6):439-44. PubMed ID: 12688834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug safety evaluation of rotigotine.
    Sprenger FS; Seppi K; Poewe W
    Expert Opin Drug Saf; 2012 May; 11(3):503-12. PubMed ID: 22468676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ropinirole therapy for Parkinson's disease.
    Pahwa R; Lyons KE; Hauser RA
    Expert Rev Neurother; 2004 Jul; 4(4):581-8. PubMed ID: 15853577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New pharmacotherapy for Parkinson's disease.
    Gottwald MD; Bainbridge JL; Dowling GA; Aminoff MJ; Alldredge BK
    Ann Pharmacother; 1997 Oct; 31(10):1205-17. PubMed ID: 9337447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pramipexole extended-release: a review of its use in patients with Parkinson's disease.
    Frampton JE
    Drugs; 2014 Dec; 74(18):2175-90. PubMed ID: 25385556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of ropinirole prolonged release in Parkinson's disease.
    Nashatizadeh MM; Lyons KE; Pahwa R
    Clin Interv Aging; 2009; 4():179-86. PubMed ID: 19503779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.
    Rascol O
    Eur J Neurol; 2011 Mar; 18 Suppl 1():3-10. PubMed ID: 21255197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine agonists: what is the place of the newer compounds in the treatment of Parkinson's disease?
    Rascol O
    J Neural Transm Suppl; 1999; 55():33-45. PubMed ID: 10335491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased risk of somnolence with the new dopamine agonists in patients with Parkinson's disease: a meta-analysis of randomised controlled trials.
    Etminan M; Samii A; Takkouche B; Rochon PA
    Drug Saf; 2001; 24(11):863-8. PubMed ID: 11665873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study.
    Garcia-Ruiz PJ; Martinez Castrillo JC; Alonso-Canovas A; Herranz Barcenas A; Vela L; Sanchez Alonso P; Mata M; Olmedilla Gonzalez N; Mahillo Fernandez I
    J Neurol Neurosurg Psychiatry; 2014 Aug; 85(8):840-4. PubMed ID: 24434037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.